Citigroup Inc Bio Line Rx Ltd. Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Citigroup Inc holds 31,337 shares of BLRX stock, worth $108,426. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,337Holding current value
$108,426% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding BLRX
# of Institutions
39Shares Held
4.24MCall Options Held
46.5KPut Options Held
6.3K-
Highbridge Capital Management LLC New York, NY1.01MShares$3.49 Million0.05% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL866KShares$3 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.82 Million4.05% of portfolio
-
Morgan Stanley New York, NY198KShares$683,4780.0% of portfolio
-
Values First Advisors, Inc.166KShares$575,9130.02% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $213M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...